The twenty third annual report on the biotech industry, Biotech 2009 -- Life Savoir: Browsing through the Sea Transform, has just recently been released. This report demonstrates the biotech industry a new profit-making time in 2008, although it turned out overshadowed by recent incidents. In this article, we're going examine a number of the challenges experienced by this market and consider possible structural alterations. We'll also consider possible new rules and institutional arrangements to improve future.

The public collateral markets have not been build to deal how to identify the best biotech companies for investment when using the problems of enterprises engaged in R&D-only activities. Biotech companies cannot be valued based on their particular earnings - most don't have any earnings - because the value depends upon ongoing R&D projects. Due to this fact, investors possess little familiarity with biotech companies' financial performance and simply cannot accurately judge their long term worth based upon a past record. In addition , there are no criteria for credit reporting intangible property and valuing unfunded R&D projects.

Although biotech businesses performed very well during the COVID-19 pandemic, they encountered challenges in access to capital and values. A recent report by Ernst & Young LLP provides an up to date snapshot of the industry as well as its future prospective clients. The record shows that the industry's long term future revenues and R&D investment funds look appealing, despite the showing signs of damage macroeconomic conditions. The record also reveals a large tide of cash waiting around to be invested in future biotech products.